DL-AP3

DL-AP3

• CAS Number: 5652-28-8
• UNSPSC Description: DL-AP3 is a competitive mGluR1 and mGluR5 antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect[1][2][3].
• Target Antigen: Endogenous Metabolite; mGluR; Phosphatase
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/dl-ap3.html
• Purity: 98.0
• Solubility: H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: NC(CP(O)(O)=O)C(O)=O
• Molecular Weight: 169.07
• References & Citations: [1]Cui D, et al. DL-2-amino-3-phosphonopropionic acid protects primary neurons from oxygen-glucose deprivation induced injury. Bosn J Basic Med Sci. 2017 Feb 21;17(1):12-16. |[2]Hawkinson JE, et al. The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur J Pharmacol. 1996 Jun 27;307(2):219-25. |[3]Xu ZH, et al. Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome. Mol Neurodegener. 2012 May 28;7:24. |[4]B.F. Kania, et al. Supraspinal basis of analgesic and clinical effects of the metabotropic glutamate mGluR1 antagonist during colonic distension in sheep. Small Ruminant Research. 2014. 117 (1).
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported